News
Positive MHRA decision for Briviact
UCB has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a label extension for seizure treatment, Briviact – also known as brivaracetam.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
UCB has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a label extension for seizure treatment, Briviact – also known as brivaracetam.